The discovery centers on what happens after a gene has been transcribed. A newly made messenger RNA contains a protein-coding sequence as well as untranslated regions that help determine how long the molecule survives, where it travels inside the cell and how efficiently it is converted into protein. At the molecule’s three-prime end, cellular machinery cuts the RNA at a selected site and adds a tail of adenine nucleotides, known as a poly(A) tail. This process, called cleavage and polyadenylation, can occur at more than one location. When a cell chooses an upstream polyadenylation signal, the resulting messenger RNA has a shorter 3′UTR; when it uses a downstream signal, the 3′UTR is longer. These alternative transcripts encode the same protein, but their regulatory behavior can be dramatically different. Shortening may remove binding sites for regulatory proteins and other factors that normally restrain gene expression, allowing cancer cells to amplify oncogenic programs without changing the protein-coding DNA itself.

The research team, led by investigators at the University of Milan and collaborating institutions in Italy, Switzerland and the United Kingdom, combined several kinds of sequencing data to reconstruct the NFYA 3′UTR landscape. They examined bulk RNA sequencing, single-cell RNA sequencing and specialized three-prime-end sequencing from prostate cancer cell lines and patient-derived material. This approach identified four functional NFYA 3′UTR isoforms, each terminating at a different polyadenylation site, although one was predominantly used across the cell lines and tissues examined. By measuring the relative use of proximal and distal polyadenylation sites, the researchers could determine whether cancer cells favored shortened or lengthened transcripts. The analysis showed a broad shift toward NFYA 3′UTR shortening in prostate cancer, rather than an isolated change in a small subgroup of tumors. The pattern was associated with higher tumor grade and metastatic disease, suggesting that RNA-end selection tracks with clinically aggressive biology.

The consequences of this shortening were substantial. Tumor samples and prostate cancer models using shorter NFYA transcripts contained more NF-YA protein, while cells with longer 3′UTRs produced less. NF-Y is a transcription factor complex that binds specific DNA elements and regulates genes involved in cell-cycle control, proliferation and other growth-related processes. NF-YA acts as a regulatory component that helps determine which genes the complex can control, so changing its abundance can reshape a large downstream transcriptional network. The investigators found that the short NFYA 3′UTR was linked to increased proliferation and other traits associated with aggressive disease. In this model, cancer progression was not driven simply by producing more NFYA messenger RNA. Instead, the tumor appeared to gain an advantage by selecting an RNA architecture that made the message more effective at generating protein.

The team also investigated how the long 3′UTR reduced NF-YA output. A longer untranslated region can contain additional docking sites for microRNAs, RNA-binding proteins and cellular transport machinery, but the experiments did not support increased microRNA-mediated repression as the main explanation. Instead, lengthening the NFYA 3′UTR reduced messenger RNA stability, impaired translation and increased retention of the transcript inside the nucleus. Messenger RNA stability determines how long a transcript remains available before degradation, while translation is the process by which ribosomes read the coding sequence and build a protein. Nuclear retention creates another bottleneck: even a transcript that has been produced may be less useful if it cannot efficiently reach the cytoplasm, where most translation occurs. Together, these effects sharply reduced the amount of NF-YA protein without eliminating the NFYA gene.

The RNA pattern also changed with the state of the cancer cell. When prostate cancer cells entered quiescence, a relatively inactive state in which proliferation pauses, they shifted toward longer NFYA 3′UTRs. A similar lengthening occurred after treatment with enzalutamide, an androgen-receptor inhibitor used in prostate cancer therapy. The observation connects NFYA RNA processing to both cellular dormancy and drug response. Prostate tumors often adapt to androgen-deprivation strategies, and treatment-resistant disease can eventually progress despite continued therapy. The study does not establish that NFYA 3′UTR lengthening explains enzalutamide’s clinical effects or that manipulating the RNA switch will overcome resistance in patients. It does, however, suggest that the choice of polyadenylation site is dynamic rather than permanently fixed and may reflect the balance between a proliferating, treatment-adapted state and a more restrained cellular condition.

To test whether the RNA-processing switch was merely associated with malignancy or could be manipulated therapeutically, the researchers used two different strategies. In one, CRISPR/Cas9-mediated deletion removed a polyadenylation signal, forcing cells away from the site that generates the shorter transcript and toward production of longer NFYA 3′UTRs. In the other, antisense oligonucleotides were designed to bind and mask polyadenylation signals. These short synthetic nucleic-acid molecules can be engineered to recognize a chosen RNA sequence and physically obstruct the proteins that assemble at a polyadenylation site. Redirecting cleavage in this way offers a potentially gene-specific intervention: rather than degrading every NFYA transcript or blocking NF-YA protein after it is made, the treatment changes which version of the transcript the cell produces. In cultured prostate cancer cells, both approaches lowered NF-YA protein and reduced phenotypes associated with tumor aggressiveness, including enhanced growth.

The strongest test came in vivo, where enforced NFYA 3′UTR lengthening also suppressed aggressive tumor traits and reduced tumor progression in experimental models. The results provide proof of concept, not a ready-made treatment. Antisense drugs must reach the relevant tumor cells, remain stable in the body, enter the correct cellular compartment and avoid unintended effects on other RNAs. Prostate tumors are biologically diverse, and the balance of polyadenylation signals and RNA-binding proteins may differ between patients, treatment histories and metastatic sites. Future studies will need to establish how reliably NFYA 3′UTR patterns predict outcome, whether they can be measured in clinical samples such as biopsies or circulating tumor material, and whether antisense-mediated remodeling is safe and durable in more representative models. Even so, the study expands the therapeutic map of cancer genetics. It shows that an oncogenic protein can be controlled not only by mutations, transcription or protein degradation, but also by the precise way its messenger RNA is finished. For prostate cancer, that overlooked decision at the end of an RNA molecule could become an important new target for precision therapy.

A new experimental study published in The Journal of Higher Education Press reports that alternative forms of focal adhesion kinase, or FAK, may represent an important and previously underexplored vulnerability in SCLC. The research, titled “Unraveling the intricacies of small cell lung cancer: FAK splicing variants as a new feature and therapeutic vulnerability of small cell lung cancer,” examined how changes in RNA processing produce FAK protein variants with properties distinct from the canonical form of the kinase. The findings suggest that these variants may influence tumor growth, invasion, and resistance to treatment.

Alternative splicing is a molecular process that allows a single gene to generate multiple messenger RNA transcripts. By selectively including or excluding specific exons, cells can produce proteins with different domains, structures, locations, and biochemical activities. This mechanism is essential in normal tissues, but it can become distorted in cancer. Abnormal splicing may create protein isoforms that support uncontrolled proliferation, alter interactions between tumor cells and their surroundings, or weaken responses to therapy. In SCLC, however, the full range and functional importance of these splicing events remain incompletely characterized.

FAK is a non-receptor tyrosine kinase that normally transmits signals generated at focal adhesions, specialized structures connecting cells to the extracellular matrix. Through its kinase activity and interactions with signaling proteins, FAK helps regulate adhesion, cytoskeletal organization, migration, survival, and mechanical responses. In many cancers, elevated FAK activity is associated with aggressive behavior and poor clinical outcomes. The new study focused on whether alternative splicing could create FAK forms that are particularly important in SCLC, where the disease’s defining genetic alterations—near-universal loss of TP53 and RB1 function—have not directly translated into effective targeted therapies.

The investigators identified FAK splicing variants that were preferentially expressed in SCLC compared with normal lung tissue and non-small cell lung cancer. According to the study, these variants arose through alternative exon inclusion or exclusion, producing proteins with altered functional characteristics. Compared with canonical FAK, the variant proteins displayed enhanced kinase activity and distinct patterns of subcellular localization. Such differences are biologically significant because the location of a signaling protein within the cell can determine which substrates it encounters and which downstream pathways it activates.

Laboratory experiments indicated that the FAK variants promoted several malignant features of SCLC cells. Cells expressing the variants showed increased proliferation, migration, and invasion, while reducing variant expression impaired tumor-associated behavior in cell-based systems and in animal models. The reported effects were linked to activation of major signaling networks, including the PI3K/AKT, MAPK, and STAT3 pathways. These pathways regulate cell survival, metabolism, proliferation, inflammatory signaling, and resistance to stress, making their coordinated activation potentially important for the highly aggressive biology of SCLC.

The study also connected FAK splicing variants to treatment resistance. SCLC is initially sensitive to chemotherapy and radiation in many patients, but surviving tumor cells can rapidly repopulate the disease. In the experiments, cells with high levels of the FAK variants displayed reduced apoptosis after exposure to chemotherapy or radiation. Apoptosis is a programmed form of cell death that many anticancer treatments are designed to trigger. Conversely, suppressing the variants increased treatment sensitivity, suggesting that altered FAK signaling may help tumor cells survive DNA damage and other stresses imposed by standard therapies.

To test the therapeutic implications of the findings, the researchers used small-molecule FAK inhibitors. These compounds reduced the kinase activity associated with the FAK variants and increased the sensitivity of SCLC cells to chemotherapy. In preclinical models, combining FAK inhibition with conventional treatment produced synergistic effects, meaning the combined response was greater than that achieved with either intervention alone. The results provide a rationale for evaluating FAK-directed combinations in SCLC, although laboratory success does not guarantee clinical benefit. Drug exposure, toxicity, tumor heterogeneity, and the ability of cancer cells to bypass blocked pathways will all require careful assessment.

The findings raise the possibility that FAK splicing variant expression could become a biomarker for selecting patients most likely to benefit from FAK-targeted therapy. They also underscore the broader importance of examining RNA processing, rather than focusing solely on DNA mutations, when searching for cancer vulnerabilities. Several questions remain unresolved, including which splicing factors drive the production of these variants, how their expression changes during tumor progression, and whether they are linked to specific SCLC subtypes or degrees of neuroendocrine differentiation. Clinical trials will ultimately be necessary to determine whether inhibiting FAK variants can improve outcomes for patients whose disease remains one of the most difficult challenges in cancer medicine.

Subject of Research: Experimental study

Article Title: Unraveling the intricacies of small cell lung cancer: FAK splicing variants as a new feature and therapeutic vulnerability of small cell lung cancer

Web References: https://doi.org/10.1007/s11684-026-1215-1

References: DOI: 10.1007/s11684-026-1215-1

Image Credits: HIGHER EDUCATION PRESS

Keywords: Small cell lung cancer, focal adhesion kinase, FAK splicing variants, alternative splicing, cancer therapy resistance, chemotherapy, radiation, PI3K/AKT, MAPK, STAT3, targeted therapy

The research focuses on the KCMF1/FUS/CENPT axis, a novel signaling pathway that has emerged from the study of tumor biology. The FUS protein, initially known for its role in RNA processing and regulation of gene expression, appears to have a multifaceted role in cancer biology, functioning beyond its traditional boundaries. In renal cell carcinoma, FUS has been shown to interact with other regulatory proteins, such as KCMF1 and CENPT, culminating in a cascade of biological events that may facilitate tumor growth and metastasis.

The study meticulously details how FUS operates within the KCMF1/FUS/CENPT axis to alter cellular behavior in RCC. The authors utilized cellular models to demonstrate that elevated levels of FUS expression correlate with aggressive features of renal tumors. This correlation underscores the potential of FUS as a therapeutic target. By inhibiting FUS activity, it may be possible to attenuate cancer cell proliferation and promote tumor cell death, presenting an innovative approach to RCC treatment.

Furthermore, the authors explored the JNK signaling pathway’s activation as a downstream effect of FUS involvement in RCC progression. The c-Jun N-terminal kinase (JNK) pathway is instrumental in regulating processes such as apoptosis and cellular growth. The researchers highlight that the interaction between FUS and JNK not only facilitates tumor survival but also enhances the inflammatory milieu of the tumor microenvironment, contributing to a more aggressive cancer phenotype. This dual role emphasizes JNK’s significance as a potential therapeutic target, working synergistically with strategies aimed at FUS inhibition.

The experimental setup included a series of in vitro assays and in vivo models to validate the findings. By employing specific inhibitors and gene knockdown techniques, the team was able to establish a clear causal relationship between FUS activity and RCC aggression. Their findings were consistent across multiple cell lines, demonstrating a robust effect that may translate across different RCC types. Such reproducibility is essential for clinical relevance and future therapeutic development.

The implications of this research extend beyond simple understanding; it proposes that targeting the KCMF1/FUS/CENPT axis may represent a transformative strategy in RCC management. As RCC is often diagnosed at an advanced stage and notoriously resistant to conventional treatments, identifying new molecular targets like FUS offers hope for more effective therapeutic options. The potential of developing drugs aimed at this pathway is significant, propelling the need for further investigation.

Notably, the study also reveals the potential for combination therapies that involve JNK inhibitors alongside FUS targeting. This synergistic approach may enhance treatment efficacy, a critical consideration in cancer therapy where resistance to single-agent treatments frequently emerges. The findings suggest a holistic view of RCC therapy, where targeting multiple pathways can disrupt the cancer’s ability to adapt and thrive in hostile environments.

In parallel, the research brings to light the need for personalized medicine approaches within RCC treatment paradigms. The varying expression levels of FUS across different patients could serve as biomarkers for prognosis and treatment responsiveness, thereby enabling tailored therapeutic strategies. This aligns with a growing trend in oncology that emphasizes the need for bespoke treatments that cater to individual patient profiles rather than a one-size-fits-all methodology.

Another compelling aspect of this research is its potential to reframe existing understanding of FUS in oncology. Traditionally viewed merely as an RNA-binding protein associated with certain malignancies, this study positions FUS as an integral player in RCC progression mechanisms. Such a shift in perception can inspire future studies to systematically investigate FUS’s role in other cancers, potentially leading to broad-spectrum cancer therapeutic strategies.

In essence, Jiang and colleagues’ work serves as a clarion call for the oncology community to invest in elucidating the complex pathways of cancer biology. The interconnectedness of molecular signaling pathways like that of KCMF1, FUS, and CENPT suggests a web of interactions that could be unraveled to reveal new targets for intervention. It invites further exploration and perhaps even the development of new investigative paradigms that focus on these intricate relationships.

As this science unfolds, the need for collaborative efforts spanning molecular biology, pharmacology, and clinical research becomes paramount. Researchers and clinicians alike must converge to expedite the translation of these findings into clinical practice, ensuring that emerging treatments based on the elucidated pathways can reach those in need efficiently. That task, while daunting, offers the potential reward of saving lives and improving outcomes for those afflicted by one of the most challenging forms of cancer.

The journey from bench to bedside is often fraught with obstacles, yet the urgency of this research provides impetus for ongoing studies. The collective mission may now include not just striving for scientific excellence but also fostering partnerships that bridge the gap between discovery and clinical application. In the fast-evolving world of cancer therapeutics, such initiatives are not only necessary but could be transformative in ensuring patient survival and improved quality of life.

In conclusion, the intricate relationship between FUS and renal cell carcinoma underscores a promising horizon for cancer research and treatment. The unveiling of the KCMF1/FUS/CENPT axis combined with the influence of JNK signaling represents a convergence of novel insights that may shift the paradigms of RCC therapy. The call to action is clear: harness these discoveries into practice, making strides towards a future where RCC can be effectively managed and possibly cured.

Subject of Research: Renal Cell Carcinoma Progression and the Role of FUS

Article Title: Fused in Sarcoma (FUS) promotes renal cell carcinoma progression via the KCMF1/FUS/CENPT axis and activation of the JNK signaling pathway.

Article References: Jiang, Z., Zhang, R., Qi, Y. et al. Fused in Sarcoma (FUS) promotes renal cell carcinoma progression via the KCMF1/FUS/CENPT axis and activation of the JNK signaling pathway. J Transl Med 23, 1207 (2025). https://doi.org/10.1186/s12967-025-07254-z

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12967-025-07254-z

Keywords: Renal cell carcinoma, Fused in Sarcoma, KCMF1, JNK signaling pathway, cancer progression, molecular pathways, targeted therapy.